RHC-80267 (83654-05-1) inhibits DAG Lipase activity in a variety of cell types and tissues, including canine platelets, bovine adrenal chromaffin cells, human adrenal glomerulosa cells, rat thyroid lobes and pancreatic minilobules. IC50 in canine platelets is 4 μM.1
RHC-80267 is a selective inhibitor of DAG lipase, which plays an important role in the production of arachidonic acid.
ChEBI: N-[6-[[(cyclohexylideneamino)oxy-oxomethyl]amino]hexyl]carbamic acid (cyclohexylideneamino) ester is a carbamate ester and an organonitrogen compound.
Selective inhibitor of DAG lipase activity in canine platelets (IC
50 = 4 nM) and in a variety of mammalian cells. Also inhibits glucose- and carbachol-induced insulin release from intact islets. An inhibitor of Angiotensin II (Cat. No.
05-23-0101) and ATP-induced synthesis of 6-keto-prostaglandin F1α.
Inhibitor of diacylglycerol lipase (IC 50 values are 1.1 and 4 μ M in rat cardiac myocytes and canine platelets respectively). Weakly inhibits phospholipases C and A 2 . Potentiates acetylcholine evoked relaxation in mesenteric arteries by the inhibition of cholinesterase activity (IC 50 = 4 μ M).
Product does not compete with ATP.
1) Southerland and Amin (1982), Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors; J. Biol. Chem., 257 14006
2) Rindlisbacher et al. (1990), Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis; J. Neurochem., 54 1247
3) Chandra Sekar et al. (1987), Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors; Arch. Biochem. Biophys., 256 509
4) Levasseur et al. (1984), Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis; Prostaglandins, 27 673
5) Natarajan et al. (1988), Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors; Biochem. Biophys. Res. Commun., 156 717
